Harnessing the microbiome
to improve health

Osel filed a new IND for CBM588 oncology indications in early 2024 and has begun a Phase 1 dose escalation trial in advanced kidney cancer with a new capsule formulation of CBM588 at the City of Hope Comprehensive Cancer Center. The study is now enrolling patients. See NCT06399419 for contact information.

Osel is pioneering a new class of medicines, Live Biotherapeutic Products
to restore health by modulating the body’s microbiome